Tag: diabetes

WORLD DIABETES DAY: Nearly 80 South Africans Die from Diabetes Daily – UP Expert Calls for Urgent National Action

An illustration of blood glucose monitoring, an important aspect of diabetes management and the prevention of complications. Source: Pixabay CC0

PRETORIA – Diabetes has remained South Africa’s leading underlying natural cause of death for three consecutive years, claiming nearly 29 000 lives in 2024 alone. A University of Pretoria (UP) public health expert is calling for urgent action to strengthen healthcare and prevent avoidable deaths.

According to the latest Statistics South Africa mortality report, 28 767 South Africans died from diabetes-related complications in 2024. This represents 6.1% of all recorded deaths, or about 79 people every day.

Diabetes was also the leading underlying natural cause of death in 2022 and 2023, with 33 126 and 27 967 deaths, respectively.

Dr Patrick Ngassa Piotie, co-founder of UP’s Diabetes Research Centre and Chairperson of the Diabetes Alliance, says these figures expose a persistent public health crisis that demands immediate intervention.

“These numbers cannot be accepted as South Africa’s new normal,” he says. “Diabetes is mostly preventable and manageable. With timely support, people can lead long, healthy lives free from preventable complications.”

Diabetes is a chronic condition in which the body cannot properly regulate blood sugar levels. Without appropriate treatment, it can cause life-threatening complications affecting the heart, kidneys, eyes, and blood vessels.

Women and working-age adults are most at risk

The national statistics reveal significant inequalities in the burden of diabetes.

In 2024, diabetes claimed 17 429 women’s lives, accounting for 7.9% of all recorded female deaths. Among men, it caused 11 334 deaths, representing 4.5% of male deaths.

Working-age South Africans are also particularly vulnerable. Diabetes was the leading natural cause of death among people aged 45 to 64, accounting for 9 364 deaths, or 7.9% of deaths in this age group.

It also ranked as the leading natural cause of death in five provinces: Gauteng, KwaZulu-Natal, Western Cape, Eastern Cape, and Limpopo.

The findings reflect a broader national health challenge, with noncommunicable diseases, including diabetes and cardiovascular conditions, accounting for 60.7% of all recorded deaths in 2024.

Why better healthcare could save lives

Dr Ngassa Piotie argues that mortality statistics tell us how many lives have been lost to diabetes, but reveal little about the circumstances surrounding those deaths, including whether they could have been prevented through earlier diagnosis, timely treatment, and better-quality care.

“We should not wait until people die to identify where our health system is failing them,” he says. “We must use the evidence available today to improve care, prevent avoidable complications, and save lives.”

Death certificates cannot reveal whether patients received timely diagnoses, had reliable access to medication, or were regularly monitored for complications.

Through UP’s Tshwane Insulin Project, researchers have demonstrated how nurse-led care can help patients with type 2 diabetes start and adjust insulin treatment at primary healthcare facilities, supported by follow-up care at home.

“Survival rarely hinges on high-tech interventions,” Dr Ngassa Piotie says.

Instead, effective diabetes care depends on trained healthcare workers, reliable medicine supplies, regular screening, continuous monitoring, and support that accommodates patients’ everyday circumstances.

From policy to action: Preventing avoidable deaths

South Africa’s National Strategic Plan for Non-Communicable Diseases includes targets known as 90-60-50. These aim to ensure that 90% of adults know their blood pressure and blood glucose status, 60% of those with elevated levels receive treatment, and 50% of those receiving care achieve clinical control.

However, translating these commitments into effective healthcare remains a challenge.

Dr Ngassa Piotie advocates for the establishment of a national diabetes registry and the integration of digital health systems to track patients from diagnosis through treatment, identify those who discontinue care, and monitor complications.

He identifies three immediate priorities: connecting early diagnosis to sustained treatment, measuring healthcare outcomes across districts and provinces, and addressing socio-economic barriers such as food insecurity, transport costs, and limited healthcare access.

Following the 2025 Diabetes Summit, the Diabetes Alliance launched the Johannesburg Declaration for Accelerated Action on Diabetes in South Africa, calling for coordinated national leadership, sustainable financing, and stronger primary healthcare.

For Dr Ngassa Piotie, preventing avoidable diabetes-related deaths requires more than awareness campaigns. It demands a coordinated national response that ensures patients receive the continuous care they need.

“People living with diabetes must help define what quality care looks like,” he says.

Read Dr Ngassa Piotie’s full article in The Conversation.

Diabetes Masks Alzheimer’s Biological Changes in the Brain

Neurons in the brain of an Alzheimer’s patient, with plaques caused by tau proteins. Credit: NIH

Research led by King’s College London suggests diabetes may mask biological changes linked to Alzheimer’s disease, raising the possibility that the underlying biology of Alzheimer’s differs between people with and without diabetes.

Diabetes is a major risk factor for Alzheimer’s disease, and the two conditions share several biological processes, including mitochondrial dysfunction, inflammation, oxidative stress and impaired insulin signalling. This suggests that diabetes may contribute to the progression of changes in the brain associated with Alzheimer’s disease.

The paper, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, examined mitochondrial DNA copy number (mtDNA-CN) in post-mortem samples from three regions of the human brain: the hippocampus, amygdala and cerebellum.

The team found that Alzheimer’s disease and diabetes were associated with opposing changes in mitochondrial DNA. Alzheimer’s was associated with lower mtDNA-CN, while diabetes was associated with higher levels across all three brain regions.

When people with diabetes were removed from the analysis, mtDNA-CN was 19 to 30 per cent lower in people with Alzheimer’s compared with cognitive controls. In contrast, among people with Alzheimer’s, those with diabetes had significantly higher mtDNA-CN than those without diabetes. Levels were 41 per cent higher in the hippocampus, 52 per cent higher in the amygdala and 64 per cent higher in the cerebellum. Surprisingly, all diabetes cases, including those with and without dementia, had higher mtDNA in these three regions than non-diabetic controls.

These opposing effects suggest that including people with diabetes in Alzheimer’s studies could reduce or mask differences associated with Alzheimer’s itself.

The findings suggest that diabetes may change the way Alzheimer’s disease is associated with mitochondrial changes, rather than simply being a background health condition. This could mean that the relationship between Alzheimer’s and mitochondrial DNA may be different in people with diabetes compared with those without diabetes.

“The key finding of our study in relation to Alzheimer’s disease is that grouping both diabetic and non-diabetic data for mtDNA-CN together can result in loss of real changes which may be important in disease mechanisms. Our research supports the growing view that Alzheimer’s disease can affect people in different ways at a biological level, and that conditions such as diabetes may contribute to these differences.”

Senior author Dr Afshan Malik

“We were surprised to find that mtDNA-CN was higher in the brains of people with diabetes. We don’t yet know whether this represents a response to cellular stress, a compensatory mechanism, or something else and what this means for the brain function. Our next step is to use multi-omics approaches to understand the biological consequences of this change and how it may affect brain function.”

First author Dr Aakruti Kaikini

The study provides a possible explanation for why previous studies of mitochondrial dysfunction in Alzheimer’s disease have produced conflicting results, potentially making it more difficult to diagnose patients.

In the future the researchers hope the results could be important for developing better ways to identify and understand Alzheimer’s disease, tailoring treatments to individual patients and designing future dementia clinical trials.

Source: King’s College London

79 Deaths a Day: South Africa’s Diabetes Crisis Needs a New Strategy

Photo by Wes Dissy on Unsplash

Patrick Ngassa Piotie, University of Pretoria

Statistics South Africa (Stats SA) recently released its report on deaths that occurred in 2024. The headline findings contain a sobering, recurring truth: diabetes was once again the country’s leading underlying natural cause of death.

In 2024 alone, 28 767 people died from complications caused by diabetes, accounting for 6.1% of all deaths nationwide. That is an average of nearly 79 deaths every day.

Diabetes also claimed the top spot in 2022 and 2023. These numbers cannot be accepted as South Africa’s new normal. Behind every data point is a human life, a grieving family and, all too often, years of encounters with a health system that missed opportunities to diagnose, treat and support people in time.

As a public health specialist and chairperson of the non-profit organisation Diabetes Alliance, I view this three-year trend as an unacceptable tragedy. Diabetes is manageable. With timely support, people can lead long, healthy lives free from preventable complications. Acknowledging this crisis is the start, but recognition must give way to political action. The Department of Health must establish a national diabetes strategy with clear targets for prevention and care. The finance minister must resource it. And the Presidency must lead a coordinated, whole-of-government response.

The broader health landscape is equally stark. Noncommunicable diseases accounted for 60.7% of all recorded deaths in 2024. The top three causes of natural death – diabetes, hypertensive diseases and cerebrovascular diseases – frequently overlap in the same individuals. Managing these interconnected conditions through isolated disease programmes makes little sense for primary care clinics or the patients navigating them.

Reading beyond the numbers

At first glance, the 2024 total is 800 deaths higher than the revised 2023 figure of 27,967 (5.8% of recorded deaths). Stats SA compiles these mortality figures from death notification forms filed through the Department of Home Affairs. Medical practitioners record the cause of death, which Stats SA then classifies using international coding standards. Late death registrations and administrative backlogs are processed retroactively; this leads to revision or updating of prior years’ totals.

The updated count for 2022 stood at 33,126, higher than diabetes deaths recorded in 2023 and 2024. Diabetes has remained South Africa’s single largest natural killer for three consecutive years.

The diabetes burden is also deeply unequal:

  • Women bear the heaviest loss: diabetes was the leading recorded natural cause among women, claiming 17,429 lives (7.9% of all female deaths) and 11,334 or 4.5% of all male deaths.
  • Working-age adults are hard hit: it ranked first among people aged 45-64, accounting for 9,364 deaths (7.9% of deaths in this group).
  • Geographic split: diabetes ranked as the top natural cause in five provinces, Western Cape, KwaZulu-Natal, Limpopo, Eastern Cape and Gauteng, while hypertensive diseases led in the remaining four provinces. These provincial rankings are not a measure of individual care quality or residency. They are a starting point for region-specific questions about access and system performance.

The geographic split shows the need to investigate whether access to diagnosis, treatment and good quality care differs between and within provinces.

A death certificate is only the final chapter

Mortality statistics record the primary cause listed on a death notification, but remain blind to what happened along the way.

They cannot tell us how many South Africans live with undiagnosed diabetes. They cannot show whether a patient had consistent access to insulin and testing supplies, whether their blood sugar was adequately controlled, or whether a simple follow-up could have prevented a fatal complication. Nor do they capture the full toll of diabetes when another condition is listed as the underlying cause.

Those are the questions we must answer while patients are still alive.

In my work on strengthening diabetes care, including the Tshwane Insulin Project – a nurse-led programme that helped people with type 2 diabetes start and adjust insulin treatment in primary care, with follow-up support at home – I have seen where care pathways break down, and where they succeed. Survival rarely hinges on high-tech interventions. It depends on the links in primary healthcare:

  • a trained clinic nurse with the time to act
  • a reliable supply chain for medicines and diagnostics
  • routine follow-up mechanisms when a patient misses an appointment
  • regular screening for kidney, eye and vascular (blood vessel) complications
  • support systems that respect the economic reality of a person’s daily life.

We need real-time clinical data that helps a facility respond today, not a national death tally published two years later.

Turning policy into frontline care

South Africa already has a framework: the National Strategic Plan for Non-Communicable Diseases and its 90-60-50 targets. This cascade aims to ensure that 90% of adults know their blood pressure and blood glucose status, 60% of those with elevated levels receive treatment, and 50% of those receiving care achieve clinical control.

The challenge is making policy work in practice.

Tools like the National Health Laboratory Service diabetes dashboard offer valuable insights into blood sugar levels control across districts. But to close the loop, South Africa urgently needs a national diabetes registry and integrated digital tracking to understand who enters care, who remains in care, and who is being left behind.

From declaration to delivery

After the 2025 Diabetes Summit, the Diabetes Alliance launched the Johannesburg Declaration for Accelerated Action on Diabetes. The declaration calls for coordinated national leadership, sustainable financing, decentralised primary care, and direct participation by people living with diabetes. It asks the Presidency to lead a multisectoral response and calls on the National Treasury and health sector to match policy commitments with financial resources.

The latest mortality report gives this agenda even more urgency. There are three practical priorities:

  1. Connect early diagnosis to sustained care. Screening is only useful if a positive result leads to uninterrupted treatment, reliable medicines, blood glucose monitoring and clinical review.
  2. Measure quality of care: publish a picture of diagnosis, treatment, retention and complication rates by district and province.
  3. Address the conditions in which health choices are made. Food prices, transport barriers and economic hardship shape health outcomes.

People living with diabetes must help define what quality care looks like. Their experience should guide national policy and daily clinic operations alike.

Patrick Ngassa Piotie, Chairperson, Diabetes Alliance; Co-founder, Diabetes Research Centre, University of Pretoria

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Stress May be Fuelling SA’s Metabolic Disease Risk

Photo by Samson Balogun on Unsplash

Chronic stress may be doing far more than affecting South Africans’ mental health – it could be contributing to the country’s growing burden of obesity, diabetes and other metabolic disorders, many of which are also major risk factors for cardiovascular disease (CVD).

While stress is often viewed as an unavoidable part of modern life, mounting scientific evidence suggests that prolonged psychological stress can trigger biological changes that increase the likelihood of developing obesity, type 2 diabetes (T2D) and CVD.

Prof Naidoo, CEO of the Heart and Stroke Foundation SA reminds us that day-to-day stressors has a cumulative effect affecting not just ones’ immune system, but also impacts eating, exercise and other vegetative signs, such as poor sleeping patterns. Ultimately, she says, the cardiovascular system has reduced capacity in the face of cumulative stressors.

This makes the stress-metabolism connection particularly relevant during Heart Awareness Month this September, when attention turns to the factors that can influence long-term heart-health.

The warning comes at a time when many South Africans are battling significant workplace and financial pressures. According to Gallup’s recent 2026 State of the Global Workplace report1, 36% of South African employees reported experiencing stress, while the 2025 Profmed Stress Index found that financial uncertainty and workplace pressure remain among the leading causes of stress among South African professionals.

The two-way relationship between stress and metabolic health (1)

“Most people understand that stress can affect their mood and sleep, but few realise that chronic stress can also disrupt the body’s metabolism,” says Nicole Jennings, spokesperson for Pharma Dynamics.

“When stress becomes chronic, the body remains in a prolonged state of alertness and continues producing elevated levels of cortisol, often referred to as the stress hormone. Over time, this can contribute to increased blood glucose levels, insulin resistance and the accumulation of harmful visceral fat around the abdominal organs in certain individuals.”

Research shows that prolonged activation of the body’s stress-response system may disrupt glucose metabolism, reduce insulin sensitivity and encourage fat storage, all of which are strongly associated with metabolic disease.

“But the relationship goes both ways. Long-term emotional or work-related stress can increase the likelihood of developing these conditions, while metabolic disorders can, in turn, alter the body’s stress-response systems, potentially increasing vulnerability to the effects of stress.

“Because metabolic disorders can disrupt the immune system and affect the brain’s chemical balance, they may intensify how the body reacts to pressure. The result is a vicious cycle where chronic stress contributes to metabolic dysfunction, and metabolic dysfunction may further impair the body’s ability to cope with stress. Prof Naidoo states that chronic stress has a negative effect on our health outcomes in ways that are not often obvious. An example of this is excessive eating during stressful episodes resulting in weight gain which is a potential driver for type 2 diabetes. Overweight and obesity is also, in turn, a driver for raised blood pressure and hypertension.

A growing metabolic health crisis

The concern is particularly relevant for South Africa, where metabolic disorders are becoming increasingly common.

According to the International Diabetes Federation (IDF), approximately 2.3 million South African adults are currently living with diabetes, representing a prevalence rate of 7.2% among adults. The country has the fourth-highest number of adults living with diabetes in Africa.

Obesity, another major risk factor for metabolic disease, remains a significant public health challenge. Approximately one in two South African adults is living with excess weight or obesity, placing millions at increased risk of diabetes, heart disease and other metabolic conditions (2).

“Many people focus on diet and exercise when discussing metabolic health, and rightly so,” says Jennings. “However, stress management is often the missing piece of the puzzle. You can be eating relatively well, but if you’re living in a constant state of stress, your body may still be experiencing metabolic consequences.” There is increasing evidence of the gut-brain connection where research is producing results that show that the type of diet you consume also plays a role in mental health and well-being says Prof Naidoo.

Why workplaces should pay attention

This highlights the important role employers can play in supporting both mental and physical health.

Studies have found that workplace stress is associated with a higher risk of developing metabolic syndrome, a cluster of conditions that includes elevated blood pressure, high blood sugar, excess abdominal fat and abnormal cholesterol levels. Together, these factors can significantly increase the risk of heart disease and stroke.

In South Africa, where economic uncertainty, job insecurity, rising living costs and demanding workloads contribute to stress levels, workplace wellness programmes could provide an important opportunity for prevention.

Small changes can make a big difference

Fortunately, Jennings says the stress-metabolism connection is not inevitable. Regular physical activity, sufficient sleep, a balanced diet, avoiding smoking, moderating alcohol intake and incorporating mindfulness practices – along with strong social support networks – have all been shown to help regulate the body’s stress response and support better metabolic health.

She encourages South Africans to view stress management not only as an essential component of mental health, but as part of a broader approach to protecting metabolic and heart health too.

“Managing stress isn’t a luxury – it’s an important part of preventing chronic disease. By recognising the impact stress has on the body and taking proactive steps to address it, individuals can improve both their mental well-being and long-term metabolic health.”

Prof Naidoo encourages those facing unmanageable stress to seek access to healthcare as there are specialist health care practitioners that are trained for stress management and mental health conditions.

Study Indicates Type 2 Diabetes Operates Differently Across Weight Profiles

Photo by I Yunmai on Unsplash

Research published in Diabetologia by Amsterdam UMC and the University of Ghana reveals that type 2 diabetes manifests in two fundamentally different ways depending on a patient’s body mass index (BMI). While type 2 diabetes in patients with a higher BMI is primarily driven by insulin resistance, the study demonstrates that in individuals within a lower BMI range, the condition is caused by the pancreas failing to produce sufficient insulin. Despite these opposing biological mechanisms, medical professionals currently treat both groups with the exact same medications.

Type 2 diabetes is generally seen as a disease associated with being overweight. In wealthy countries that picture holds true: nine out of ten people with type 2 diabetes are overweight. In Africa the situation is different. Almost four in ten African adults with type 2 diabetes are lean, with a normal or even low body weight. In some rural areas, such as in Ghana, it is as many as six in ten. First Author Sabrina Esmail: “This means that there are an estimated ten million lean patients on the African continent who do not fit the standard picture. For them, the problem is therefore a shortage of insulin, not a reduced response to insulin.” Projectleader Charles Agyemang at Amsterdam UMC believes “this study shows that we need to look for better treatments for this large group of lean Africans.”

A different disease process, so a different treatment too

Yet in Africa both groups are almost always given the same treatment, based on international guidelines: oral tablets such as metformin or sulfonylureas. These medicines, however, are mainly effective against insulin resistance, not against a shortage of insulin. They are therefore probably receiving the wrong treatment, and until now the consequences of this had not been investigated. 

The researchers analysed data from more than 3300 African adults with type 2 diabetes from Ghana, Nigeria, Kenya and Europe. “From this we concluded that lean patients more often develop eye damage, known as retinopathy, and strokes. People who are overweight, by contrast, more often have high blood pressure and an increased risk of cardiovascular disease. Chronic kidney disease occurred equally often in both groups,” says senior author Felix Chilunga. The amount of body fat explained the greater part of these differences, which points to genuinely different disease processes. The risk factors differ as well: whereas being overweight is often linked to an unhealthy lifestyle, lean patients have more often experienced malnutrition or a low birth weight, which can disrupt the development of the pancreas.

Type 2 diabetes in lean Africans is therefore, biologically and clinically, a different type of disease from the one seen in people who are overweight. But it is still being treated as though it were the same. As a result, millions of people may not be receiving the right care. Chilunga: “We are calling for targeted clinical trials to determine which treatment works best for this large and often overlooked group of patients.”

Africans in Europe

For Africans in Europe, too, it is very likely that a different treatment is needed. Another study with analysis from data from the UK Biobank showed that people of African descent with a BMI of 26 already have the same diabetes risk as Europeans with a BMI of 30. Studies of migrants in Europe consistently show that Africans are more likely to have type 2 diabetes, develop it around ten years earlier, and have poorer blood sugar control than the native population. Agyemang: “So a considerable proportion of African patients in Europe have a lower BMI but are treated according to guidelines written for the form of the disease found in people who are overweight, and their control is demonstrably worse. There is no reason to assume that the treatment mismatch we describe stops at the border.”

This study was carried out by Amsterdam UMC, University of Ghana, the national Institutes of Health (Center for Research on Genomics and Global Health) via de cohorts AADM and RODAM. The findings were published today in Diabetologia.

Source: Amsterdam UMC

Choosing Safer Diabetes Medications for Older Adults

Photo by Kampus Production

Older adults with type 2 diabetes face a difficult trade-off: they are among the most vulnerable to medication-related harms yet are often underrepresented in the clinical trials that guide treatment decisions. A new study led by Yuan Lu, ScD, helps address this gap by providing large-scale, real-world evidence about the safety of commonly used diabetes medications.

Published in Nature Communications, the study analysed data from more than 1.8 million people aged 65 and older across the United States and Europe. The researchers compared four major classes of second-line antihyperglycaemic medications – typically prescribed when first-line therapy such as metformin is not sufficient – across 18 safety outcomes.

“Evidence from clinical trials often does not fully capture older adults,” says Lu, assistant professor of medicine (cardiovascular medicine) at Yale School of Medicine. “They are more likely to experience side effects due to frailty, multiple chronic conditions, and the use of several medications at the same time.”

Newer diabetes drugs show overall safety advantages

The study found a consistent pattern: newer classes of medications, including GLP-1 receptor agonists and SGLT2 inhibitors, were generally associated with lower risks of several important adverse outcomes compared to older drugs such as sulfonylureas and DPP-4 inhibitors.

Newer agents were linked to lower risks of hypoglycaemia, hyperkalaemia, and peripheral oedema – complications that can be especially dangerous in older adults. However, the findings also highlight important trade-offs. For example, SGLT2 inhibitors were associated with a higher risk of diabetic ketoacidosis, while GLP-1 receptor agonists were more likely to cause gastrointestinal side effects such as nausea and vomiting.

Rather than identifying a single “best” medication, Lu emphasises that the results support more informed, individualised decision-making. “Some patients may have a higher risk of hypoglycaemia, while others may be more susceptible to diabetic ketoacidosis,” she says. “These risks need to be considered together as part of an individual patient profile.”

Real-world data at a global scale

A key strength of the study is its scale and approach. The analysis drew on nine large databases and was conducted through the Observational Health Data Sciences and Informatics (OHDSI), an international research network that enables standardized analyses across diverse health care systems.

By using harmonised real-world data and consistent analytic methods, the researchers were able to evaluate a broad range of safety outcomes in routine clinical practice – offering insights that complement and extend findings from randomised trials.

Supporting safer prescribing for an aging population

As the population ages and the use of newer diabetes medications continues to grow, understanding their safety profiles in older adults is increasingly important. The findings reinforce current guideline recommendations that often favour newer agents, while also underscoring the need to tailor treatment decisions to each patient’s risks and preferences.

Like all observational studies, the analysis cannot fully rule out unmeasured differences between patients. Still, the large, multinational design gives a more complete picture of medication safety in a population often underrepresented in clinical research.

Looking ahead, Lu and her colleagues hope to expand this work to examine the comparative safety of individual medications and to evaluate the safety of newer GLP-1 receptor agonists across a wider range of outcomes, including among people with obesity. “By providing more evidence in populations that clinicians see every day, our goal is to support safer, more informed care,” she says.

Source: Yale School of Medicine

Could a Living Implant End Daily Insulin Injections?

The development of a self-regulating, implantable living technology that could offer hope for millions with diabetes and other chronic diseases

The crystal capsules developed by the researchers. They made the cover of Science Translational Medicine.

A pioneering study marks a major step toward eliminating the need for daily insulin injections for people with diabetes. The research introduces a living, cell-based implant that can function as an autonomous artificial pancreas, essentially a living drug that is long-term, thanks to a novel crystalline shield technology.

Once implanted, the system operates entirely on its own: it continuously senses blood-glucose levels, produces insulin within the implant itself, and releases the exact amount needed – precisely when it is needed. In effect, the implant becomes a self-regulating, drug-manufacturing organ inside the body, requiring no external pumps, injections, or patient intervention.

One of the study’s most significant breakthroughs addresses the longstanding challenge of immune rejection, which has limited the success of cell-based therapies for decades. The researchers developed engineered therapeutic crystals that shield the implant from the immune system, preventing it from being recognised as a foreign object. This protective strategy enables the implant to function reliably and continuously for several years.

The technology has already been successfully tested in a mouse model for effective and long-term regulation of glucose levels and in non-human primates for cell viability and functionality. These results represent a critical milestone and strongly support the potential for future translation to human patients.

From Postdoctoral Insight to Global Collaboration

The study was led by Assistant Professor Shady Farah of the Faculty of Chemical Engineering at the Technion – Israel Institute of Technology, in co-correspondence with MIT, and in collaboration with Harvard University, Johns Hopkins University, and the University of Massachusetts. Asst Prof Farah began developing the concept with colleagues in 2018 during his postdoctoral fellowship at MIT and Boston Children’s Hospital/Harvard Medical School, under the supervision of Prof Daniel Anderson and Prof Robert (Bob) Langer, a world leader in tissue engineering and co-founder of Moderna.

Today, the research continues in Asst Prof Farah’s laboratory at the Technion, in close collaboration with leading US institutions, including MIT, Harvard, the University of Massachusetts, Boston Children’s Hospital, and the Johns Hopkins University School of Medicine.

A Platform with Far-Reaching Potential

While the immediate focus is diabetes, the researchers emphasise that this implantable, closed-loop platform could be adapted to treat a wide range of chronic conditions requiring continuous delivery of biological therapeutics – including haemophilia and other metabolic or genetic diseases.

If successfully translated to the clinic, this technology could redefine how chronic diseases are treated, shifting from repeated drug administration to living, self-regulating therapies that work seamlessly from within.

To read the full article, click here

Source: TECHNION Israel Institute of Technology

Sitting for Long Stretches Raises Heart and Diabetes Risks – Even in Active Older Adults

Photo by JD Mason on Unsplash

Spending too long sitting raises the risk of heart disease and diabetes in people over 60, warns a major global review. Published in the Journal of Physical Activity and Health, the review analysed data from 28 international studies involving 82 000 people aged 60 and older.

It flags strong links between sitting time and worsening markers for chronic disease including high blood sugar, cholesterol, waist size, and blood pressure. And that’s even for people who exercise regularly.

That means — whether watching TV, using a tablet or reading a book — the longer older people sit, the higher their risk of major health problems like heart disease, stroke, and type 2 diabetes.

“This is a link we can’t ignore,” said Dr Daniel Bailey, Reader in Sedentary Behaviour and Health at the Department of Life Sciences, Brunel University of London. “You can meet the weekly exercise target, but if you spend the rest of the day sitting, your health is still at risk.”

In the UK, where more than 12 million people are aged 65 or older, older adults can spend up to 80% of their waking hours sitting down and longer during winter or for people with mobility issues. That means millions may be unknowingly accumulating risks day after day — a concern for families, carers, and health professionals.

One of the most revealing findings was that the harmful effect of sitting for long periods showed up even in otherwise healthy older adults, not just those already diagnosed with illness. Waist measurement, a major predictor of health risk, had the strongest, most consistent link with sitting time.

“We’re seeing these impacts in people who don’t yet feel unwell,” said Dr Bailey. “That means we have a chance to intervene early and protect health before problems start.”

Importantly, the study found limited protective effect from exercise alone. After accounting for how active people were, the damage from long hours of sitting remains.

“The evidence is clear. We urgently need strategies that don’t just encourage exercise, but also help people sit less throughout the day,” said Dr Bailey. “Simple changes make a difference —standing during phone calls, replacing some TV time with gardening or a stroll, or light chores around the house.”

The study by Brunel University of London, the University of Lincoln, Federation University in Australia, and the University of Bedfordshire is the most comprehensive analysis to date linking sedentary behaviour to cardiometabolic risk in later life. As the NHS contends with rising rates of diabetes and heart disease, it spells out to policymakers that keeping moving throughout the day is as vital as structured exercise.

Dr Bailey stressed the shared role of public services, community groups and healthcare professionals to help older people avoid sitting for long stretches: “From GP advice to local councils and charities, there’s a role for everyone in changing the message.”

Source: Brunel University of London

Men at Greater Risk of Major Health Effects of Diabetes than Women

Cases of cardiovascular, leg/foot, kidney complications, and eye disease all higher in men
Sex differences in complication rates persist regardless of disease duration

Photo by Photomix Company on Pexels

Men are at greater risk than women of the major health effects of diabetes (types 1 and 2), suggests a long term study published online in the Journal of Epidemiology & Community Health.

Rates of cardiovascular disease, leg, foot, and kidney complications, and the sight-threatening eye disease diabetic retinopathy are all higher in men, regardless of whether they had diabetes for more or less than 10 years, the findings show.

The global prevalence of diabetes is similar in men and women, and is projected to rise to 783 million by 2045, note the researchers.

But while cardiovascular disease is more common in men, overall, it’s not clear if this sex difference is apparent in the incidence of the complications associated with diabetes, say the researchers. Nor is it clear whether the length of time lived with diabetes might be influential, they add.

To explore this further, the researchers drew on survey responses from the 45 and Up Study, Australia, a large prospective study of 267 357 people over the age of 45 living in New South Wales (NSW).

These responses were linked to medical records for a total of 25 713 people, all of whom had either type 1 or type 2 diabetes, to monitor the development of any of the major health issues associated with diabetes

These include cardiovascular disease – ischaemic heart disease, mini stroke or TIA, stroke, heart failure, diabetic cardiomyopathy; eye problems – cataract, diabetic retinopathy; leg/foot problems – peripheral neuropathy (nerve damage), ulcers, cellulitis, osteomyelitis (bone inflammation), peripheral vascular disease (poor circulation), and minor or major amputation; and kidney problems – acute kidney failure, chronic kidney disease, chronic kidney failure, dialysis, and kidney transplant.

Almost half of the group were aged 60 to 74, and over half (57%; 14,697) were men, a higher proportion of whom were overweight (39% vs 29% of women) and had a history of heart disease.

Although a similar proportion of men and women were current smokers, a higher proportion of men were ex-smokers: 51% vs  29% of the women.

Of the 19 277 (75%) people with diabetes whose age was recorded at their diagnosis, 58% had been living with the disease for less than a decade and 42% had lived with it for 10 or more years.

Men had higher rates, and were at greater risk, of the complications associated with diabetes.

Over an average monitoring period of 10 years, and after factoring in age, 44% of the men experienced a cardiovascular disease complication while 57% had eye complications. Similarly, 25% of the men had leg/foot complications, and 35% kidney complications. The equivalent figures for women were, respectively, 31%, 61%, 18% and 25%.

Overall, men were 51% more likely to develop cardiovascular disease than women, 47% more likely to have leg and foot complications, and 55% more likely to have kidney complications.

Although there was little difference in the overall risk of eye complications between the sexes, men were at slightly higher risk (14%) of diabetic retinopathy.

While complication rates rose in tandem with the number of years lived with diabetes for both men and women, the sex difference in complication rates persisted.

By way of an explanation, the researchers point out that the men in the study were more likely to have well known risk factors. Men may also be less likely to make lifestyle changes, take preventive meds, or get health checks to lower their risks, they suggest.

This is an observational study, and as such, no firm conclusions can be drawn about causal factors, added to which people with a history of complications were excluded from the study. And information on potentially influential factors, such as diabetes medications, and glucose, blood fat, and blood pressure control wasn’t available.

But based on their findings, the researchers suggest: “For every 1000 people with diabetes, our findings suggest that an average of 37, 52, 21, and 32 people will develop cardiovascular disease, eye, lower limb, and kidney complications every year.”

While the risks of complications are lower in women with diabetes, they are still high, emphasise the researchers.

And they conclude: “Although men with diabetes are at greater risk of developing complications, in particular [cardiovascular disease], kidney and lower-limb complications, the rates of complications are high in both sexes.

“The similar sex difference for those with shorter compared with longer diabetes duration highlights the need for targeted complication screening and prevention strategies from the time of diabetes diagnosis.

“Further investigation into the underlying mechanisms for the observed sex differences in diabetes complications are needed to inform targeted interventions.”

Source: BMJ Group

Empagliflozin and Nasal Insulin Improve Brain Health in Early Alzheimer’s Disease

Created with Gencraft. CC4.0

A clinical trial from Wake Forest University School of Medicine shows that two widely available medications, the diabetes drug empagliflozin (Jardiance) and intranasal insulin, safely improve brain health in people with mild cognitive impairment and early Alzheimer’s disease. The study, published in Alzheimer’s & Dementia, marks the first time empagliflozin has been tested in non-diabetic patients with Alzheimer’s disease. The results show promising effects on memory, brain health and brain blood flow.

The research addresses a critical treatment gap for patients with Alzheimer’s disease. While recently approved anti-amyloid drugs represent progress, their benefits are modest, and they’re unavailable to many patients due to side effects and medical contraindications. They also don’t address the upstream metabolic and vascular problems that drive disease progression or help restore brain function after damage occurs.

“Our study suggests that targeting metabolism can change the course of Alzheimer’s disease,” said Suzanne Craft, PhD, lead investigator and professor of medicine and director of the Wake Forest Alzheimer’s Disease Research Center. “For the first time, we found that empagliflozin, an established diabetes and heart medication, reduced markers of brain injury while restoring blood flow in critical brain regions. We also confirmed that delivering insulin directly to the brain with a newly validated device enhances cognition, neurovascular health and immune function. Together, these findings highlight metabolism as a powerful new frontier in Alzheimer’s treatment.”

The four-week trial enrolled 47 older adults (average age 70) with mild cognitive impairment or early Alzheimer’s disease. Participants were randomly assigned to receive intranasal insulin alone, empagliflozin alone, both medications together or a placebo. 

Both medications were safe and well-tolerated. Treatment-related side effects were mild and similar across all groups. Participants found the nasal insulin device highly feasible to use (4.6 out of 5.0), and compliance rates exceeded 97% for both medications throughout the study.

The results revealed different benefits for each medication. Intranasal insulin improved performance on sensitive cognitive tests that detect early memory and thinking changes. Brain imaging showed insulin treatment increased the structural integrity of white matter connections and changed blood flow patterns in memory-critical regions. The treatment also reduced plasma GFAP, a marker of astrocyte (support cells that maintain healthy connections between blood vessels and brain cells) dysfunction that’s elevated in Alzheimer’s disease. 

Empagliflozin had different effects. The medication significantly lowered cerebrospinal fluid tau, a protein that forms toxic tangles in the brain in patients with Alzheimer’s disease. It also reduced neurogranin and vascular markers linked to disease progression and changed blood flow in key brain regions. Empagliflozin also increased HDL cholesterol, showing its beneficial metabolic effects work even in non-diabetic patients.

Both medications influenced multiple immune and inflammatory proteins in cerebrospinal fluid and blood. The changes suggest the drugs help activate protective immune responses while reducing harmful inflammation. Intranasal insulin particularly affected proteins involved in the nasal-olfactory plexus, a newly discovered pathway that connects the brain’s waste-clearance system to immune systems throughout the body.

The medications work differently but target overlapping problems. Empagliflozin, originally developed for diabetes, improves how the body processes glucose and sodium. That leads to better insulin sensitivity and vascular health throughout the body and brain. The drug also reduces oxidative stress and inflammation while improving how mitochondria produce energy in cells.

Intranasal insulin uses a precision delivery device to send insulin directly into the brain through the nose, bypassing the bloodstream. Once there, insulin activates receptors throughout the brain that keep synapses healthy, support blood vessel function, maintain white matter integrity, and regulate immune responses. Previous studies showed that lower doses of intranasal insulin preserved brain glucose metabolism and slowed white matter damage over 12 months.

The trial used higher insulin doses than previous studies (160 IU daily versus 40-80 IU) delivered through a cartridge pump system developed by Aptar Pharma and validated in earlier brain imaging studies. This device provides precise, reliable delivery to brain regions involved in memory and cognition. Empagliflozin was given at the standard 10 mg daily dose used for cardiovascular conditions in non-diabetic adults.

People with Alzheimer’s disease often have insulin resistance in the brain alongside vascular problems that reduce blood flow and nutrient delivery. These metabolic and vascular disruptions speed up the accumulation of amyloid plaques and tau tangles while preventing the brain from clearing these toxic proteins. Both medications tested in this trial target these upstream problems. 

“We plan to build on these promising results with larger, longer studies in people with early and preclinical Alzheimer’s disease,” Craft said. “Because empagliflozin or intranasal insulin improved tau tangles, cognition, neurovascular health and immune function, we believe these treatments could offer real therapeutic potential, either on their own or in combination with other Alzheimer’s therapies.”

The complementary effects of the two medications could make them valuable additions to combination therapy approaches. Since both drugs are already FDA-approved for other conditions with well-established safety profiles, they could reach patients faster than entirely new medications would.

Source: Wake Forest University School of Medicine